Blog
Working notes for exosome brand owners: QC reading guides, claim-compliance checklists, and the capacity math behind small-batch production.
Blog · Insights
Article list
Blog 01 · Insights
Ten Questions to Ask Any Exosome Supplier Before You Sign
Consumer exposés keep catching supplement and skincare suppliers overclaiming. A ten-point supplier vetting checklist for exosome brand owners — docum
Blog 02 · Insights
Exosome Claims: What You Can Say, and What Gets Brands Fined
Exosome claims are where brands die quietly — FDA warning letters, Chinese market-regulator notices, six-figure fines. A working map of the claim ladd
Blog 03 · Insights
Open Handling Pays Three Hidden Taxes. A Closed Line Removes All Three.
Open exosome handling pays three hidden taxes — contamination loss, batch inconsistency and documentation gaps. The industry's own survey numbers make
Blog 04 · Insights
What a Real EV COA Contains: Seven Items and the Red Flags That End the Call
Seven items a trustworthy exosome COA should carry — batch traceability, named methods, size and concentration, endotoxin, sterility, payload checks a
Blog 05 · Insights
What Keeps Exosomes Alive in Transit: −20/−80 Lanes and the 60/360-Day Windows
Exosome logistics is a designed system, not a courier choice: dual-temperature material lanes, validated stability windows per format, reconstitution
Blog 06 · Insights
How to Compare Two EV COAs in Ten Minutes
Two fictional COAs, read line by line — a worked comparison showing where the real differences hide (methods, limits, traceability) and how a ten-minu
Blog 07 · Insights
5B to 100B Particles/mL: Which Concentration Tier Your Program Needs
Concentration is a dose decision, not a marketing number. The tier ladder from 5 to 100 billion particles/mL, which program families sit where, and th
Blog 08 · Insights
What an Exosome Program Really Costs: Five Buckets and the MOQ Ladder
A structural cost anatomy of an exosome program — formula, labor, packaging, compliance, and the MOQ ladder — built on published industry benchmarks,
Blog 09 · Insights
Launching Exosome SKUs in the EU: 1223/2009, CPNP and PIF, Step by Step
The EU route in practice: what Regulation 1223/2009 restricts, what a PIF must contain, who the Responsible Person is, what a CPSR costs, and the nano
Blog 10 · Insights
Particle Count Isn't Purity: The Five Lines That Decide Your Pilot
A line-by-line walkthrough of an exosome spec sheet from the buyer's chair: what particle count proves, what it hides, and the five questions that tur
Blog 11 · Insights
Evening Rituals: A Food-Track Quick-Dissolve Between Pharma and Herbal
Sleep-adjacent products split into prescription weight and herbal vagueness. The documented middle — a quick-dissolve ritual with a real material chai
Blog 12 · Insights
The Evidence Hierarchy: Where Each Exosome Claim Actually Sits
Every exosome claim sits on a four-rung ladder — published reviews, registered investigations, internal observational programs, case files. How to loc
Blog 13 · Insights
Freeze-Dry Design: The Four Phases, the Protectant System and the Protocol Card
Lyophilized EV powder is the shipping-stability format — and the easiest one to get wrong. The four-phase freeze-dry program, the cryoprotectant syste
Blog 14 · Insights
Flask vs. Closed Micro-Batch Line: Pricing a 500-Unit Exosome Pilot
Culture flasks scale by footprint and labor; closed micro-batch lines scale by program count. The capacity equation explained — and why the pilot batc
Blog 15 · Insights
Oral EV supplements: the DSHEA route in the US, the novel-food route in the EU
Oral exosome formats live under food law, not cosmetics law: DSHEA structure/function discipline in the US, the EU food-supplement and novel-food fram
Blog 16 · Insights
Pet Longevity: the veterinary-first exosome window is open
Veterinary regenerative medicine is a quarter-billion-dollar market compounding past 12%; the veterinary EV segment is headed toward $700M by 2033 — a
Blog 17 · Insights
Post-Procedure Aftercare: a protocol, not a moisturizer
The industry saying is three parts treatment, seven parts care — yet aftercare is a shelf pick, not a protocol. The 0-to-30-day window, the product la
Blog 18 · Insights
Purification recovery >95%: the number that sets your exosome unit cost
Purification is 40%+ of exosome production cost, and every recovered percentage point is margin. The recovery-to-unit-economics math — plus the storag
Blog 19 · Insights
Eye comfort for the screen generation: the open slot on beauty's most conservative shelf
Eye care is the most conservative shelf in beauty, and the screen generation outgrew it. What registered clinical investigations of preservative-free
Blog 20 · Insights
How a 0–100 Seed Score Decides What Gets Manufactured
Batch consistency is decided upstream, at seed selection. Inside the AI scoring method: the 22,554-entry library, the 0–100 potential screen, the ~93%
Blog 21 · Insights
Senior Gifting: Beauty's Fastest-Growing Occasion Runs on Proof, Not Ribbon
The 55+ recipient is beauty's fastest-growing gifting audience — and the shelf answers with ribboned generics. The buyer psychology, the demand data,
Blog 22 · Insights
20 Questions That Separate an Exosome Manufacturer from a Repackager
Twenty questions in four stages — documentation, manufacturing, compliance, logistics — that sort real exosome manufacturers from repackagers, before
Blog 23 · Insights
US MoCRA for Exosome Brands: Five Obligations and One Sentence
MoCRA in practice for exosome SKUs: biennial facility registration, 120-day product listing, the US Agent requirement, adverse-event clocks, the under
Blog 24 · Insights
Exosome QC 101: Reading NTA, TEM and Sterility Lines on a COA
A QC characterization primer for brand owners and product teams: the methods behind each test item on a batch release sheet — NTA, TEM, sterility and
Other tracks
Go deeper after the blog
The whitepaper compiles the full methodology, selection through compliance. The Solutions track shows it applied, category by category.